Forbes contributors publish independent expert analyses and insights. CEO, Innovation Leader Passionate about Modernizing via AI Identifying and accelerating drug development is big business. The ...
The most striking evidence that artificial intelligence can provide profound scientific breakthroughs came with the unveiling of a program called AlphaFold by Google DeepMind. In 2016 researchers at ...
Artificial-intelligence tools that enable companies to share data about drug candidates while keeping sensitive information safe can unleash the potential of machine learning and cutting-edge lab ...
The drug development pipeline is a costly and lengthy process. Identifying high-quality "hit" compounds-those with high potency, selectivity, and favorable metabolic properties-at the earliest stages ...
It’s been 10 months since the FDA declared a shortage of Adderall, a medication for the treatment of attention deficit hyperactivity disorder (ADHD) that is prescribed in brand name and ...
Duxin Sun receives funding from the NIH, FDA, and pharmaceutical industries including Bristol-Myers Squibb, Celgene Corporation, Aurinia Pharmaceuticals, Abbvie, Nanomedicine Innovation Center.
Katie Palmer covers telehealth, clinical artificial intelligence, and the health data economy — with an emphasis on the impacts of digital health care for patients, providers, and businesses. You can ...
In the UK, there was a case where TGN1412, an immunotherapy under development, triggered a cytokine storm within hours of administration to humans, leading to multiple organ failure. Another example, ...
Despite significant progress in medicinal chemistry and life sciences research, drug discovery and development remain slow and expensive, taking on average approximately 15 years and US$2 billion to ...
Baritinib is a drug to treat rheumatoid arthritis. After outbreak of COVID-19, Benevolent AI Company discovered that AAK1 is a regulatory factor in the process of SARS-CoC-2 infection by generating a ...
Understanding and preventing drug side effects holds a profound influence on drug development and utilization, profoundly impacting patients’ physical and mental well-being. Traditional artificial ...
This analysis is by Bloomberg Intelligence Industry Analyst Andrew Galler and Senior Associate Analyst Jack Maltby. It appeared first on the Bloomberg Terminal. Life sciences is among the most ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback